Methods and compositions for treating excessive sleepiness
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.
1. A method of improving excessive sleepiness in a human patient in need thereof, said method comprising administering [R]-2-amino-3-phenylpropylcarbamate (APC) or a pharmaceutically acceptable salt thereof to the human patient in accordance with a dosing regimen, said dosing regimen comprising a once-daily dose of 75 mg for at least 3 days followed by a once-daily dose of 150 mg, wherein the once-daily dose of 150 mg is the maximum dose in the dosing regimen, thereby improving excessive sleepiness in the human patient.
2. The method of claim 1 , wherein the dosing regimen comprises a starting dose of 75 mg once daily for 3 days followed by a dose of 150 mg once daily.
3. The method of claim 1 , wherein the dosing regimen comprises a starting dose of 37.5 mg once daily.
4. The method of claim 1 , wherein the patient has a baseline Epworth Sleepiness Scale (ESS) score greater than 10.
5. The method of claim 1 , wherein the excessive sleepiness is excessive daytime sleepiness.
6. The method of claim 1 , wherein the APC is provided as a pharmaceutically acceptable salt of APC.
7. The method of claim 6 , wherein the APC is in the form of a hydrochloride salt.
8. The method of claim 1 , wherein the patient has narcolepsy.
9. The method of claim 1 , wherein the patient has obstructive sleep apnea.
10. A method of treating excessive sleepiness in a human patient with obstructive sleep apnea in need thereof, said method comprising administering [R]-2-amino-3-phenylpropylcarbamate (APC) or a pharmaceutically acceptable salt thereof to the human patient in accordance with a dosing regimen, said dosing regimen comprising a once-daily dose of 75 mg for at least 3 days followed by a once-daily dose of 150 mg, wherein the once-daily dose of 150 mg is the maximum dose in the dosing regimen, thereby treating excessive sleepiness in the human patient.
11. The method of claim 10 , wherein the dosing regimen comprises a starting dose of 75 mg once daily for 3 days followed by a dose of 150 mg once daily.
12. The method of claim 10 , wherein the dosing regimen comprises a starting dose of 37.5 mg once daily.
13. The method of claim 10 , wherein the patient has a baseline ESS score greater than 10.
14. The method of claim 10 , wherein the excessive sleepiness is excessive daytime sleepiness.
15. The method of claim 10 , wherein the APC is provided as a pharmaceutically acceptable salt of APC.
16. The method of claim 15 , wherein the APC is provided in the form of a hydrochloride salt.